FT113

Cas No.:	1630808-89-7
Chemical Name:	[4-(6-Fluoro-1,3-benzoxazol-2-yl)phenyl]-[4-(1-hydroxycyclopropanecarbonyl)piperazin-1-yl]methanone
Synonyms:	FT113;BCP31017;BCP30637;ZB1585;s6666;(4-(4-(6-fluorobenzo[d]oxazol-2-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone;[4-(6-Fluoro-1,3-benzoxazol-2-yl)phenyl]-[4-(1-hydroxycyclopropanecarbonyl)piperazin-1-yl]methanone
SMILES:	FC1C([H])=C([H])C2=C(C=1[H])OC(C1C([H])=C([H])C(=C([H])C=1[H])C(N1C([H])([H])C([H])([H])N(C([H])([H])C1([H])[H])C(C1(C([H])([H])C1([H])[H])O[H])=O)=O)=N2
Formula:	C22H20FN3O4
M.Wt:	409.4103
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:	FT113 is a potent and orally active fatty acid synthase (FASN) inhibitor, with an IC50 of 213 nM for full-length recombinant human FASN enzyme. In cell-based assay, FT113 blocks FASN activity in BT474 cells (IC50, 90 nM). FT113 shows anti-proliferative activity, and exhibits anti-cancer both in vitro and in vivo[1].
Target:	IC50: 213 nM (FASN), 90 nM (FASN, in BT474 cell)[1]
In Vivo:	FT113 (5 mg/kg, p.o.) exhibits potent oral bioavailability of 95% and 84% in mice and rats, respectively[1]. FT113 (5, 25, or 50 mg/kg, p.o., twice daily for 16 days) increases malonyl-CoA concentration in tumors, inhibits tumor growth in a dose-dependent manner in mice[1].
In Vitro:	FT113 shows anti-proliferative activity against PC3 and MV-411 cells with IC50s of 47 and 26 nM, respectively[1].
References:	[1]. Martin MW, et al. Discovery and optimization of novel piperazines as potent inhibitors of fatty acid synthase (FASN). Bioorg Med Chem Lett. 2019 Apr 15;29(8):1001-1006.